No trials are being conducted at this time.

NeOnc Technologies is continuing ongoing studies to determine the benefit of the TMZ/POH conjugate. Early pre-clinical research shows that NEO 212 is ten times more potent, five times less toxic than TMZ, five times more stable, and three times more effective blood-brain barrier penetrance compared to TMZ on its own.

NEO 212 has been tested in acute and chronic (small and large animal) testing at Charles Rivers in Montreal, Canada in an oral formulation, with the dose-limiting toxicity of myelotoxicity. It has also been examined in non-GLP testing for intranasal delivery at Charles Rivers in Willmington, Maryland. Orphan drug status for malignant gliomas has been granted and by year-end it is hoped that application for Investigational New Drug (IND) status will be completed.

The primary target for Temozolomide (TMZ) is glioblastoma multiforme. It is estimated that close to 25, 000 people in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord this year. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors. Since treatment using TMZ is generally through a series of oral dosages or by intravenous infusion, its effectiveness is inhibited by the need for uptake to occur through the intestinal or circulatory system. Primary side-effects include bone marrow suppression, nausea, vomiting, constipation, loss of appetite, and more. 

NEO 212 hopes to improve efficacy while minimizing the side-effect issues currently associated with TMZ treatment.

NeOnc Technologies continues its research into the ability of its NEO 214 formulation to enhance the ability of Rolipram to be used in the treatment of cognitive disorders. To date, the company has been able to show that Rolipram delivered via the NEO 214 wrapper is 1,000 times more potent than oral Rolipram alone.

Rolipram is classified as a  phosphodiesterase type 4 inhibitor (PDE4) because of its ability to block the action of phosphodiesterase type 4 enzymes from breaking the messenger bonds between cAMP molecules which are critical to regulating the biological activity of proteins. As such PDE4 is seen as a potential strong agent in being able to treat neuro-cognitive issues such as Alzheimer's, to provide improved long term memory, increased wakefulness, increased neuroprotection, and to assist in faster recovery for axonal regeneration and spinal cord lesions.

Additionally, PDE4 has been shown to reduce the effects of respiratory inflammation in issues such as asthma and COPD.

No trials are currently being conducted at this time.

Though the exact mechanisms of VPA are still being studied, it is believed that it works by affecting GABA levels in the brain thereby blocking voltage-gated sodium channels, and inhibiting histone deacetylases which are associated with seizures. Studies have shown that VPA is helpful in decreasing seizures associated with Epilepsy and brain trauma as well as being an anti-manic depressant for those with bipolar disease. VPA has also proven effective in decreasing the pain and effects of migraine headaches and has even shown some preliminary positive therapeutic results in treating Schizophrenia.

A research paper is pending publication.

3-Bromopyruvate (3BP) is being studied as a general anti-cancer therapeutic. The drug has the ability to inhibit the energy production of cancer cells thus slowing or preventing growth. The compound works by addressing the "Warburg Effect" of cancer cells that shows how cancer cell reproduction has an abnormal dependence on metabolizing glucose even when sufficient oxygen is present, which is how normal cells proliferate. By blocking the ability of cancer cells to uptake glucose, cell growth is reduced. 

Delivery of the drug though is one of the key factors in limiting efficacy due to side-effects of its toxicity to other systems and its need to travel systemically through the body to get to a tumor site where potency can be degraded. NEO 218 promises to bring a much higher efficacy to 3BP therapy by providing immediate, full potency delivery of the therapeutic to patients suffering from brain cancer. 

No trials are being conducted at this time.

It is estimated that about one million Americans are thought to have Parkinson’s. This is more than those affected by multiple sclerosis, muscular dystrophy, and amyotrophic lateral sclerosis (ALS) combined. The combined direct and indirect costs of Parkinson’s in the U.S. including treatment, disability, and similar costs, plus lost income from an inability to work, are estimated at $25 billion per year. The average cost of Parkinson’s medication is $2,500 per year. Parkinson’s-related surgery can cost up to $100,000 per patient. Dopamine-based therapy still remains one of the most common drug therapies used to combat Parkinson's.

NEO 312 promises to offer an a cost-effective and targeted solution to Dopamine delivery to treat this disease in order to provide better outcomes from those suffering from Parkinson's.

NeOnc Technologies is currently conducting a human study on the effects of its NEO 400 topical skin therapy in decreasing wrinkles and dry skin. As Linoleic Acid (LA) is an Omega-6 essential fatty acid, it has proven to be able to provide moisture and “plumpness” to surface epidermis without weighing down the skin. Combined with our POH base, preliminary data suggests NEO 400 can increase the effectiveness of LA in increasing in epidermal thickness, improved cell turnover, and increased cell differentiation in the stratum corneum. It also shows an impact on lightening sun-induced hyperpigmentation. 

If the trial data is successful, a determination will be made whether NEO 400 could be added to the consumer OTC products that limit exposure to UV rays but provide no specific protection for cancer prevention.

As a topical skin treatment NEO400 shows great promise in providing both preventative and restorative benefits for skin damage caused by intense UV exposure. NeOnc Technologies is fast-tracking its research and approval certification paperwork in order to begin the regulatory approval process. As a topical cream, NEO 400 can be approved through the less restrictive and time-consuming cosmetic approval process and it can be sold as a non-controlled OTC product. As such NEO400 could be revenue-producing in as little as 12-18 months.

NeOnc Technologies has conducted research that showed that NEO 412 tested in a subcutaneous melanoma model on mice demonstrated a successful decrease in tumor size using a cutaneous (topical) application. Additional testing showed that NEO 412 also shows promise in actinic keratosis and skin melanomas in human volunteers.

Further testing is being conducted to show efficacy in treating melanomas, basal cell carcinoma, cutaneous T-cell lymphomas, and neurinomas.

NEO 412 is targeted as a therapeutic for those suffering a variety of early-stage skin cancers where local topical treatment may prove efficacious as opposed to surgical procedure which is more costly and has more potential side effects.

NeOnc Technologies hopes to provide a viable treatment option for the more than 9,500 people who are diagnosed with skin cancer each and every day in the U.S. It is estimated that 196,060 cases of melanoma will be diagnosed in the U.S. in 2020. Of those, 95,710 cases will be in situ (noninvasive) melanomas where NEO 412 may offer effective relief.

No trials are being conducted at this time.

NeOnc Technologies is continuing ongoing studies to determine the benefit of the TMZ/POH conjugate. Early pre-clinical research shows that NEO 212 is ten times more potent, five times less toxic than TMZ, five times more stable, and three times more effective blood-brain barrier penetrance compared to TMZ on its own.

NEO 212 has been tested in acute and chronic (small and large animal) testing at Charles Rivers in Montreal, Canada in an oral formulation, with the dose-limiting toxicity of myelotoxicity. It has also been examined in non-GLP testing for intranasal delivery at Charles Rivers in Willmington, Maryland. Orphan drug status for malignant gliomas has been granted and by year-end it is hoped that application for Investigational New Drug (IND) status will be completed.

The primary target for Temozolomide (TMZ) is glioblastoma multiforme. It is estimated that close to 25, 000 people in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord this year. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors. Since treatment using TMZ is generally through a series of oral dosages or by intravenous infusion, its effectiveness is inhibited by the need for uptake to occur through the intestinal or circulatory system. Primary side-effects include bone marrow suppression, nausea, vomiting, constipation, loss of appetite, and more.

NEO 212 hopes to improve efficacy while minimizing the side-effect issues currently associated with TMZ treatment.

NeOnc Technologies continues its research into the ability of its NEO 214 formulation to enhance the ability of Rolipram to be used in the treatment of cognitive disorders. To date, the company has been able to show that Rolipram delivered via the NEO 214 wrapper is 1,000 times more potent than oral Rolipram alone.

Rolipram is classified as a  phosphodiesterase type 4 inhibitor (PDE4) because of its ability to block the action of phosphodiesterase type 4 enzymes from breaking the messenger bonds between cAMP molecules which are critical to regulating the biological activity of proteins. As such PDE4 is seen as a potential strong agent in being able to treat neuro-cognitive issues such as Alzheimer's, to provide improved long term memory, increased wakefulness, increased neuroprotection, and to assist in faster recovery for axonal regeneration and spinal cord lesions.

Additionally, PDE4 has been shown to reduce the effects of respiratory inflammation in issues such as asthma and COPD.

No trials are currently being conducted at this time.

Though the exact mechanisms of VPA are still being studied, it is believed that it works by affecting GABA levels in the brain thereby blocking voltage-gated sodium channels, and inhibiting histone deacetylases which are associated with seizures. Studies have shown that VPA is helpful in decreasing seizures associated with Epilepsy and brain trauma as well as being an anti-manic depressant for those with bipolar disease. VPA has also proven effective in decreasing the pain and effects of migraine headaches and has even shown some preliminary positive therapeutic results in treating Schizophrenia.

A research paper is pending publication.

3-Bromopyruvate (3BP) is being studied as a general anti-cancer therapeutic. The drug has the ability to inhibit the energy production of cancer cells thus slowing or preventing growth. The compound works by addressing the "Warburg Effect" of cancer cells that shows how cancer cell reproduction has an abnormal dependence on metabolizing glucose even when sufficient oxygen is present, which is how normal cells proliferate. By blocking the ability of cancer cells to uptake glucose, cell growth is reduced. 

Delivery of the drug though is one of the key factors in limiting efficacy due to side-effects of its toxicity to other systems and its need to travel systemically through the body to get to a tumor site where potency can be degraded. NEO 218 promises to bring a much higher efficacy to 3BP therapy by providing immediate, full potency delivery of the therapeutic to patients suffering from brain cancer. 

No trials are being conducted at this time.

It is estimated that about one million Americans are thought to have Parkinson’s. This is more than those affected by multiple sclerosis, muscular dystrophy, and amyotrophic lateral sclerosis (ALS) combined. The combined direct and indirect costs of Parkinson’s in the U.S. including treatment, disability, and similar costs, plus lost income from an inability to work, are estimated at $25 billion per year. The average cost of Parkinson’s medication is $2,500 per year. Parkinson’s-related surgery can cost up to $100,000 per patient. Dopamine-based therapy still remains one of the most common drug therapies used to combat Parkinson's.

NEO 312 promises to offer an a cost-effective and targeted solution to Dopamine delivery to treat this disease in order to provide better outcomes from those suffering from Parkinson's.

NeOnc Technologies is currently conducting a human study on the effects of its NEO 400 topical skin therapy in decreasing wrinkles and dry skin. As Linoleic Acid (LA) is an Omega-6 essential fatty acid, it has proven to be able to provide moisture and “plumpness” to surface epidermis without weighing down the skin. Combined with our POH base, preliminary data suggests NEO 400 can increase the effectiveness of LA in increasing in epidermal thickness, improved cell turnover, and increased cell differentiation in the stratum corneum. It also shows an impact on lightening sun-induced hyperpigmentation. 

If the trial data is successful, a determination will be made whether NEO 400 could be added to the consumer OTC products that limit exposure to UV rays but provide no specific protection for cancer prevention.

As a topical skin treatment NEO400 shows great promise in providing both preventative and restorative benefits for skin damage caused by intense UV exposure. Neonc Technologies is fast-tracking its research and approval certification paperwork in order to begin the regulatory approval process. As a topical cream, NEO 400 can be approved through the less restrictive and time-consuming cosmetic approval process and it can be sold as a non-controlled OTC product. As such NEO 400 could be revenue-producing in as little as 12-18 months.

Neonc Technologies has conducted research that showed that NEO 412 tested in a subcutaneous melanoma model on mice demonstrated a successful decrease in tumor size using a cutaneous (topical) application. Additional testing showed that NEO 412 also shows promise in actinic keratosis and skin melanomas in human volunteers.

Further testing is being conducted to show efficacy in treating melanomas, basal cell carcinoma, cutaneous T-cell lymphomas, and neurinomas.

NEO 412 is targeted as a therapeutic for those suffering a variety of early-stage skin cancers where local topical treatment may prove efficacious as opposed to surgical procedure which is more costly and has more potential side effects.

NeOnc Technologies hopes to provide a viable treatment option for the more than 9,500 people who are diagnosed with skin cancer each and every day in the U.S. It is estimated that 196,060 cases of melanoma will be diagnosed in the U.S. in 2020. Of those, 95,710 cases will be in situ (noninvasive) melanomas where NEO 412 may offer effective relief.